E
Enliven Therapeutics, Inc. (ELVN)
NMS – Real vaqt narxi. Valyuta: USD
42.30
+2.71 (6.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
42.30
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 5:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
42.30
+2.71 (6.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
42.30
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 5:00 AM EDT
Enliven Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton bilan kasallangan bemorlarga yordam berish uchun kichik molekulyar ingibitorlarni kashf qilish va ishlab chiqishga qaratilgan. Uning klinik dasturlari orasida surunkali miyeloid leykemiya bilan kasallangan kattalarni davolash uchun 1-faza klinik sinovlarida bo'lgan kichik molekulyar kinaza ingibitori ELVN-001; va markaziy asab tizimiga (MS) kirib boradigan va qaytarilmas inson epidermis o'sish omili retseptorlari 2 ingibitori ELVN-002 mavjud bo'lib, u 1-faza klinik sinovlarida mayda hujayrali o'pka saratonini (NSCLC) va boshqa HER2 mutatsiyasiga ega o'smalarni davolash uchun ishlatiladi. Kompaniya 2019 yilda tashkil etilgan va shtab-kvartirasi Kolorado shtatining Bouldr shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development |
| Mr. Richard A. Fair M.B.A. | CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | elvn-20260507.htm |
| 2026-05-07 | 10-Q | elvn-20260331.htm |
| 2026-04-27 | DEFA14A | d948532ddefa14a.htm |
| 2026-04-15 | PRE 14A | d948512dpre14a.htm |
| 2026-03-03 | S-8 | d189577ds8.htm |
| 2026-01-07 | 8-K | d28332d8k.htm |
| 2025-12-16 | S-8 | d63864ds8.htm |
| 2025-12-11 | 8-K | d937094d8k.htm |
| 2025-11-13 | 8-K/A | elvn-20251112.htm |
| 2025-11-12 | 10-Q | elvn-20250930.htm |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder & Head of Pipeline |